NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis $5.26 +0.07 (+1.35%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Champions Oncology Stock (NASDAQ:CSBR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Champions Oncology alerts:Sign Up Key Stats Today's Range$5.00▼$5.2350-Day Range$5.19▼$6.8852-Week Range$5.00▼$8.74Volume457 shsAverage Volume8,110 shsMarket Capitalization$73.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. Read More Champions Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreCSBR MarketRank™: Champions Oncology scored higher than 11% of companies evaluated by MarketBeat, and ranked 860th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingChampions Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -64.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -64.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 17.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Champions Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 7.85.Change versus previous monthShort interest in Champions Oncology has recently decreased by 1.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.68 News SentimentChampions Oncology has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Champions Oncology this week, compared to 2 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSBR Stock News HeadlinesChampions Oncology (NASDAQ:CSBR) Stock Price Passes Below 200 Day Moving Average - Here's What HappenedAugust 4 at 3:23 AM | americanbankingnews.comChampions Oncology, Inc. (CSBR) Q4 2026 Earnings Call TranscriptJuly 27, 2026 | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 7 at 1:00 AM | Chaikin Analytics (Ad)Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 MillionJuly 27, 2026 | finanznachrichten.deChampions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | finanznachrichten.deChampions Oncology, Inc.: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 31, 2026 | finanznachrichten.deChampions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 Earnings Call TranscriptMarch 14, 2026 | insidermonkey.comChampions Oncology, Inc. (CSBR) Q3 2026 Earnings Call TranscriptMarch 12, 2026 | seekingalpha.comSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How have CSBR shares performed this year? Champions Oncology's stock was trading at $6.9250 at the beginning of the year. Since then, CSBR shares have decreased by 24.9% and is now trading at $5.2040. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings results on Monday, July, 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06. The biotechnology company earned $13.84 million during the quarter, compared to analyst estimates of $12.89 million. Champions Oncology had a negative trailing twelve-month return on equity of 27.48% and a negative net margin of 1.87%. Read the conference call transcript. Who are Champions Oncology's major shareholders? Top institutional shareholders of Champions Oncology include Bank of New York Mellon Corp (0.16%). View institutional ownership trends. How do I buy shares of Champions Oncology? Shares of CSBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings7/27/2026Today8/07/2026Next Earnings (Estimated)9/14/2026Fiscal Year End4/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CSBR's financial health is in the Yellow zone, according to TradeSmith. CSBR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CSBR CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year Founded2007Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-1.87% Pretax Margin-1.56% Return on Equity-27.48% Return on Assets-3.84% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.96 Sales & Book Value Annual Sales$59.42 million Price / Sales1.22 Cash Flow$0.01 per share Price / Cash Flow364.36 Book Value$0.29 per share Price / Book18.03Miscellaneous Outstanding Shares13,890,000Free Float7,367,000Market Cap$72.64 million OptionableOptionable Beta0.40 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CSBR) was last updated on 8/7/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSBR Stock Alerts